Patent · US Active

PCSK9 peptide combination vaccine and method of use

US9669079B2 · kind B2 · utility

0Cited by

0References

20Claims

0Family size

Assignee

AFFIRIS AG · AT

Inventors

Sylvia Brunner · Wien, AT
Gergana Galabova · Wien, AT
Bettina Wanko · Wien, AT
Markus Windwarder · Gänserndorf, AT
Gabriele Winsauer · Wien, AT
Guenther Staffler · Wien, AT
Claudia Juno · Wien, AT

Key dates

Filing date	Oct 23, 2015
Grant date	Jun 6, 2017
Priority date	—
Expiry date	Oct 23, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y304/21061
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a immunogen comprising at least two fragments of Proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein at least two fragments comprise at least 8 consecutive amino acid residues of amino acid residues 150 to 170 and/or 205 to 225 of PCSK9 (SEQ ID NO:9).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.